Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-10-21

Clinical Trial Update: Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of omalizumab in adults aged 18-70 with moderate to severe chronic urticaria; the trial is completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis | Conditions: Chronic Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2011-10-21